Globally, the risk of new variants of Corona has been seen increasing rapidly in the last few months. The researchers found that new variants such as Aris (EG.5.1) and Pirola (BA.2.86) increased the risk of infection. Recent reports suggest that infection with these variants has increased the number of patients in hospitals and the number of deaths in some parts of the UK, including the UK. Researchers found that the new variants have more mutations than the original variants, due to which they can easily infect people by dodging the immunity built in the body.
Meanwhile, the team of scientists has created vaccines targeting new variants of Corona, which was also approved by the Food and Drug Administration (FDA) on Monday. Researchers found that this vaccine can help protect infants and the elderly from the threat of the deadly respiratory virus RSV and new variants of Corona.
The team of scientists hopes that with the help of this newly updated vaccine, can also help reduce the health risks caused by new variants.
Who will need these vaccines?
The Centers for Disease Control and Prevention (CDC) has called an advisory meeting on Tuesday (September 12) to decide who needs these vaccines or whether everyone should be given updated vaccines for protection. In which a decision has to be taken.
It is noteworthy that Pfizer-BioNTech and Moderna have prepared new vaccine shots, and preliminary research reports have found them to be effective against mutations in the variants. After the decision on vaccines is taken on Tuesday, vaccines can be sent to all parts of the country.
What do experts say?
Dr. Peter Marks, the top vaccine expert at the FDA, says vaccination can help reduce the risks of death, along with health problems and hospitalization, caused by corona. Officials say that the updated vaccines may help prevent the binding of the spike protein of the new variants and reducing the risk of infection in the body. This can also reduce the risks of death.
Moderna's updated vaccine
American vaccine manufacturer Moderna has updated its COVID-19 vaccine to target new variants. According to data released by the company, the updated vaccine may help reduce problems in the body due to additional mutations in the spike protein for the XBB.1.5 sublineage of SARS-CoV-2.
Last week, the clinical trial data shared by the company confirmed that the vaccine can help boost the immune response against BA.2.86.
Pfizer vaccines have also been found effective
Apart from Moderna, Pfizer company has also manufactured vaccines targeting new variants. Its pre-clinical data shows that this vaccine can generate antibody responses in the body against other sub-variants of Omicron, including XBB.1.5, BA.2.86 (Pirola), and EG.5.1 (Aris). Due to the BA.2.86 variant, many countries have seen rapidly increasing cases of infection and the number of patients in hospital. These vaccines can help protect the body against new variants.
(PC: Freepik)
